- Home
- ANAB vs NYMT Comparison
ANAB vs NYMT Comparison
Compare ANAB & NYMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- NYMT
- Stock Information
- Founded
- ANAB 2005
- NYMT 2003
- Country
- ANAB United States
- NYMT United States
- Employees
- ANAB N/A
- NYMT N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- NYMT Real Estate Investment Trusts
- Sector
- ANAB Health Care
- NYMT Real Estate
- Exchange
- ANAB Nasdaq
- NYMT Nasdaq
- Market Cap
- ANAB 630.2M
- NYMT 615.9M
- IPO Year
- ANAB 2017
- NYMT 2004
- Fundamental
- Price
- ANAB $21.90
- NYMT $7.37
- Analyst Decision
- ANAB Buy
- NYMT Strong Buy
- Analyst Count
- ANAB 10
- NYMT 4
- Target Price
- ANAB $48.00
- NYMT $7.81
- AVG Volume (30 Days)
- ANAB 465.1K
- NYMT 557.4K
- Earning Date
- ANAB 11-04-2025
- NYMT 10-29-2025
- Dividend Yield
- ANAB N/A
- NYMT 11.27%
- EPS Growth
- ANAB N/A
- NYMT N/A
- EPS
- ANAB N/A
- NYMT 0.19
- Revenue
- ANAB $123,164,000.00
- NYMT $205,403,000.00
- Revenue This Year
- ANAB $11.22
- NYMT $9.04
- Revenue Next Year
- ANAB $8.35
- NYMT $22.80
- P/E Ratio
- ANAB N/A
- NYMT $36.97
- Revenue Growth
- ANAB 304.17
- NYMT 23.27
- 52 Week Low
- ANAB $12.21
- NYMT $5.02
- 52 Week High
- ANAB $40.70
- NYMT $7.27
- Technical
- Relative Strength Index (RSI)
- ANAB 52.43
- NYMT 64.58
- Support Level
- ANAB $19.86
- NYMT $6.92
- Resistance Level
- ANAB $22.98
- NYMT $7.23
- Average True Range (ATR)
- ANAB 1.00
- NYMT 0.17
- MACD
- ANAB 0.35
- NYMT 0.04
- Stochastic Oscillator
- ANAB 69.14
- NYMT 100.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NYMT New York Mortgage Trust Inc.
New York Mortgage Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Distressed residential assets such as residential mortgage loans sourced from distressed markets and non-Agency RMBS. Second mortgages, Agency RMBS, and certain other mortgage-related and residential housing-related assets. Geographically operates in USA states California, New York, Florida, New Jersey, Illinois, maximum from California.